Avenzo

Avenzo Therapeutics to Share Phase 1 AVZO-021 (CDK2 Inhibitor) Data at the 2026 American Society of Clinical Oncology Annual Meeting

Avenzo Therapeutics to Present New Phase 1 Data on AVZO-021 (CDK2 Inhibitor) at the 2026 American Society of Clinical Oncology Annual Meeting Avenzo Therapeutics has announced a significant milestone in its ongoing efforts to develop innovative cancer therapies, revealing that…

Read MoreAvenzo Therapeutics to Share Phase 1 AVZO-021 (CDK2 Inhibitor) Data at the 2026 American Society of Clinical Oncology Annual Meeting
Synthekine

Synthekine Reports Strong STK-012 Activity in First-Line NSCLC at AACR 2026

Synthekine Reports Updated Clinical and Translational Findings for STK-012 in First-Line Non-Squamous NSCLC at AACR 2026 Synthekine, a clinical-stage biotechnology company focused on precision cytokine therapeutics, has released updated clinical and translational data for its investigational therapy STK-012. The results…

Read MoreSynthekine Reports Strong STK-012 Activity in First-Line NSCLC at AACR 2026
Personalis

Personalis Showcases ctDNA Monitoring & Resistance Tracking at AACR 2026

Personalis Showcases Advanced ctDNA Monitoring & Therapy Resistance Insights at AACR 2026 Personalis, has unveiled a series of compelling clinical findings and technological advancements at the American Association for Cancer Research Annual Meeting 2026, highlighting the growing clinical value of…

Read MorePersonalis Showcases ctDNA Monitoring & Resistance Tracking at AACR 2026